Rifabutin 150 MG

DRUG3 trials

Sponsors

Konstantopoulio-Patission General Hospital of Nea Ionia, University of Bari, Institut de Recherche en Santé (IRSS)

Conditions

Antibiotic Resistant InfectionAntibiotic Resistant StrainHIV/AIDS TuberculosisHelicobacter Pylori Infection

Phase 3

Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.

University of BariAntibiotic Resistant Infection, Antibiotic Resistant Strain, Helicobacter Pylori Infection

Start: 2020-01-14End: 2022-04-14Target: 362Updated: 2021-01-12

Phase 4

Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.

Konstantopoulio-Patission General Hospital of Nea IoniaHelicobacter Pylori Infection

Start: 2019-09-01End: 2020-02-28Target: 304Updated: 2019-09-19

Unknown Phase

Rifabutin with lopinavir/ritonavir in patients coinfected with tuberculosis and HIV in Burkina Faso

RecruitingPACTR201310000629390

Institut de Recherche en Santé (IRSS)HIV/AIDS Tuberculosis

Start: 2013-11-28Target: 30Updated: 2026-01-27

Related Papers

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.

2020-06-262 citations

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Annals of Clinical Microbiology and Antimicrobials2020-01-224 citations